IRLAB Therapeutics AB (publ) (STO:IRLAB.A)
Sweden
· Delayed Price · Currency is SEK 7.29
-0.11 (-1.49%)
May 9, 2025, 5:29 PM CET
IRLAB Therapeutics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 98.99 | 94.63 | 5.68 | 61.14 | 207.78 | - | Upgrade
|
| Other Revenue | 3.7 | - | - | - | - | 0.3 | Upgrade
|
| Revenue | 102.69 | 94.63 | 5.68 | 61.14 | 207.78 | 0.3 | Upgrade
|
| Revenue Growth (YoY) | 1708.47% | 1566.57% | -90.71% | -70.58% | 69160.67% | -19.36% | Upgrade
|
| Cost of Revenue | 132.2 | 136.29 | 128.41 | 125.91 | 81.74 | 65.63 | Upgrade
|
| Gross Profit | -29.52 | -41.66 | -122.73 | -64.77 | 126.05 | -65.33 | Upgrade
|
| Selling, General & Admin | 46.92 | 46.18 | 53.08 | 42.48 | 31.02 | 23.97 | Upgrade
|
| Other Operating Expenses | -14.87 | -17.31 | -0.04 | -0.03 | 38.97 | 0.01 | Upgrade
|
| Operating Expenses | 36.6 | 33.45 | 57.36 | 47.23 | 73.47 | 26.23 | Upgrade
|
| Operating Income | -66.12 | -75.11 | -180.09 | -112 | 52.58 | -91.56 | Upgrade
|
| Interest Expense | -13.95 | -10.48 | -0.2 | -0.3 | -0.37 | -0.2 | Upgrade
|
| Interest & Investment Income | 2.46 | 2.46 | 3.13 | - | 0 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | -0.68 | -1.11 | -0.43 | 0.1 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.48 | - | 0 | - | - | -0 | Upgrade
|
| EBT Excluding Unusual Items | -78.08 | -83.13 | -177.84 | -113.41 | 51.78 | -91.65 | Upgrade
|
| Pretax Income | -78.08 | -83.13 | -177.84 | -113.41 | 51.78 | -91.65 | Upgrade
|
| Earnings From Continuing Operations | -78.08 | -83.13 | -177.84 | -113.41 | 51.78 | -91.65 | Upgrade
|
| Net Income | -78.08 | -83.13 | -177.84 | -113.41 | 51.78 | -91.65 | Upgrade
|
| Net Income to Common | -78.08 | -83.13 | -177.84 | -113.41 | 51.78 | -91.65 | Upgrade
|
| Shares Outstanding (Basic) | 52 | 52 | 52 | 52 | 52 | 48 | Upgrade
|
| Shares Outstanding (Diluted) | 52 | 52 | 52 | 52 | 52 | 48 | Upgrade
|
| Shares Change (YoY) | - | - | 0.07% | 0.16% | 8.54% | 17.45% | Upgrade
|
| EPS (Basic) | -1.51 | -1.60 | -3.43 | -2.19 | 1.00 | -1.92 | Upgrade
|
| EPS (Diluted) | -1.51 | -1.60 | -3.43 | -2.19 | 1.00 | -1.92 | Upgrade
|
| Free Cash Flow | -21.25 | -65.79 | -165.14 | -145.49 | 127.93 | -89.61 | Upgrade
|
| Free Cash Flow Per Share | -0.41 | -1.27 | -3.18 | -2.81 | 2.47 | -1.88 | Upgrade
|
| Gross Margin | -28.75% | -44.03% | - | -105.94% | 60.66% | - | Upgrade
|
| Operating Margin | -64.39% | -79.38% | -3171.72% | -183.20% | 25.30% | -30520.67% | Upgrade
|
| Profit Margin | -76.04% | -87.85% | -3132.07% | -185.50% | 24.92% | -30551.00% | Upgrade
|
| Free Cash Flow Margin | -20.69% | -69.52% | -2908.47% | -237.97% | 61.57% | -29869.33% | Upgrade
|
| EBITDA | -61.53 | -70.5 | -179.17 | -111.27 | 53.07 | -91.23 | Upgrade
|
| EBITDA Margin | -59.92% | -74.50% | - | -182.00% | 25.54% | - | Upgrade
|
| D&A For EBITDA | 4.58 | 4.61 | 0.92 | 0.74 | 0.49 | 0.33 | Upgrade
|
| EBIT | -66.12 | -75.11 | -180.09 | -112 | 52.58 | -91.56 | Upgrade
|
| EBIT Margin | -64.39% | -79.38% | - | -183.20% | 25.30% | - | Upgrade
|
| Revenue as Reported | 122.14 | 114.08 | 5.72 | 61.28 | 207.91 | 0.4 | Upgrade
|
Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.